AI주식인사이트AI Stock Insight
C

HEM파마

376270KOSDAQ

49.3 / 100

Reference Date: 2026-09-08

Financial Score12.5 / 40
News Sentiment18.8 / 25
Momentum6.0 / 20
Disclosure12.0 / 15
AI Analysis: ROE is below the industry average, Operating Profit is on a declining trend. Declined 10.7% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

HEM Pharma is a global microbiome specialist company offering personalized healthcare services and LBP (Live Biotherapeutic Products) discovery platforms. Utilizing its proprietary PMAS technology, the company simulates microbiome environments to provide customized solutions and collaborates with global pharmaceutical firms and Amway, expanding into markets such as Japan and Vietnam.

Number of Employees

101people

Average Salary

55.3M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 15.004.0Point
PBR
—Industry Average 1.203.5Point
ROE
-151.43Industry Average 8.000.0Point

Well below industry avg

Debt Ratio
117.61Industry Average 100.002.0Point

Higher than industry avg (caution)

Trend 2023~20253.0 / 10 points
Revenue Growth Rate
3.0 / 3

Avg ▲84.0% (2-year basis)

Operating Profit Growth Rate
0.0 / 3

Avg ▼34.1% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -82.9% (declining, 3yr)

Detailed News Sentiment

7 totalPositive 5Neutral 2Negative 0Average Sentiment Score 75

Detailed Momentum

52-week position3.0Point

52w lower range (20%)

Current 37,600Won52-week high 94,00052-week low 23,100
1-month return1.0Point

1m -10.69% (falling)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

6 totalPositive 1Neutral 5Negative 0
  • Positive[기재정정]단일판매ㆍ공급계약체결2026-09-04
  • Neutral반기보고서 (2026.06)2026-08-21
  • Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-08-20
  • Neutral주식등의대량보유상황보고서(일반)2026-08-20
  • Neutral기업설명회(IR)개최2026-08-19